39 / 51
Page 95
Journal of Clinical Immunology and Allergy
ISSN: 2471-304X
E u r o p e a n C o n g r e s s o n
Vaccines & Vaccination
and Gynecologic Oncology
Vaccines & Vaccination and Gynecologic Oncology 2018
O c t o b e r 2 6 - 2 7 , 2 0 1 8
B u d a p e s t , H u n g a r y
Introduction:
Pneumonia is one of the most important causes of morbidity and mortality in children under 5 in Egypt, and the
Ministry of Health of Egypt is considering introducing pneumococcal conjugate vaccine (PCV) in its national immunization
program. We performed an economic analysis to evaluate the cost-effectiveness of this vaccine in Egypt and to provide the
decision-makers with needed evidence.
Methods:
The analysis was done using theTRIVACmodel. Data included demographic characteristics, burden of disease, coverage
and efficacy of the vaccine, health resource utilization and costs of pneumococcal disease vaccination and treatment. Whenever
possible, we used national or regional data. Two alternatives were compared: (1) general vaccination of children younger than
5 years with the 13-valent pneumococcal conjugate vaccine (PCV13), using a three-dose schedule without booster, and (2) no
vaccination. Outcomes of 10 cohorts from birth to 5 years were analyzed. The study was performed from the governmental
perspective and selected public health providers.
Results:
In comparison to no vaccine, the introduction of PCV13 would be cost-effective, with an incremental cost-effectiveness
ratio of US$ 3916 per disability-adjusted life-year (DALY) averted (government perspective). The total incremental cost of the PCV
vaccination program (10 cohorts) would be approximately US$ 1.09 billion. Over the 10 cohorts, the program would avert 8583
pneumococcal deaths-42% of all pneumococcal-related deaths.
Conclusion:
The introduction of PCV13 would be a good value for money from the government perspective. It would represent
a high-impact public health intervention for Egypt and respond to the National Immunization Technical Advisory Group (NITAG)
resolution on reducing pneumonia burden and overall child mortality. Strengthening surveillance will be critical in generating high-
quality national data, improving future economic analyses that support evidence-based decisions for introducing vaccines and
public health interventions, and in monitoring their impact.
sibakmohammed@gmail.comCost-effectiveness analysis of the introduction
of the pneumococcal conjugate vaccine (PCV-13) in
the Egyptian national immunization program, 2013
Sibak Mohammed
Egypt
Journal of Clinical Immunology and Allergy, Volume: 4
DOI: 10.21767/2471-304X-C2-006
Euro Vaccines 2018